Lead Product
ellennbe's lead product in the field of immune-mediated inflammatory diseases (IMIDs)
is a new and innovative therapeutic approach.
We currently cover the following indications:
Rheumatology
-
Rheumatoid Arthritis (RA)
-
Polyarthritis
-
Ankylosing Spondylitis
-
Polymyalgia Rheumatica
Gastroenterology
-
Morbus Crohn
-
Ulcerative Colitis
Others
-
Basedow's disease
First clinical results in patients have been impressive, with reductions in both inflammation and swelling, and proven efficacy in long-term treatment. Patients report a distinctly higher quality of life soon after initial treatment.
The following treatment benefits are identified:
-
First effects within 24 hours (reduction of pain and stiffness)
-
Curative character under long-term treatment
-
May be used together with standard treatments other than JAK inhibitors
-
Self-application is possible
-
Superior side-effect profile
Two single case studies are illustrated below:
Rheumatoid Arthritis
1
Under regular treatment, excellent disease control for over two years is achieved (treatment is ongoing). After the second treatment, the patient slept through the night and could walk forward down the stairs for the first time in years. There has been no loss of efficacy. At present, the patient does not have any joint complaints at all.
Furthermore, within the first two weeks of ellennbe’s treatment a decrease in the amount of tender and swollen joints, and in patient’s rating of pain, impairment due to RA and disease activity was observed and have been maintained until today.
2
Previous treatments with TNF-α inhibitors, JAK inhibitors, or DMARDs including MTX failed. The patient was under treatment with tocilizumab, still suffering severely from disease symptoms such as swollen and inflamed joints.
Additional treatment with ellennbe's novel treatment method resulted in a significant reduction in HAQ-score after 6 weeks. Similar to the patient above, within the first two weeks of ellennbe’s treatment a decrease in the amount of tender and swollen joints, and in patient’s rating of pain, impairment due to RA and disease activity was observed and have been maintained until today.
After 16 weeks, the treatment with tocilizumab was discontinued without any effect on the improved health condition.
The patient underwent finger surgery shortly before treatment start to reduce synovitis among others. Under treatment with ellennbe‘s technology, there has been no reactivation of synovitis on the finger joints.
Assessment of CRP was not informative in this patient due to the use of tocilizumab, an IL-6 inhibitor. However, after tocilizumab discontinuation, no increase in CRP was observed.
